This mechanism agrees with the observation that statins, which reduce ROS production by NADPH oxidases via inhibition of Rac1, are effective in acute models of AF and in patients with post-operative AF, but fail to do so in models of long-lasting AF or patients with permanent AF. Here, FMO5 is linked to atrial fibrillation.